Monaco Asset Management SAM Takes Position in QuidelOrtho Corporation $QDEL

Monaco Asset Management SAM acquired a new stake in shares of QuidelOrtho Corporation (NASDAQ:QDEL) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 65,000 shares of the company’s stock, valued at approximately $1,138,000. QuidelOrtho comprises about 0.1% of Monaco Asset Management SAM’s holdings, making the stock its 26th largest holding. Monaco Asset Management SAM owned approximately 0.10% of QuidelOrtho at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Global Retirement Partners LLC grew its stake in shares of QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after acquiring an additional 886 shares during the period. Camelot Portfolios LLC bought a new position in QuidelOrtho during the fourth quarter valued at approximately $29,000. Hantz Financial Services Inc. boosted its holdings in QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after purchasing an additional 362 shares during the last quarter. Larson Financial Group LLC boosted its holdings in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after purchasing an additional 1,015 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in QuidelOrtho by 67.7% in the 2nd quarter. GAMMA Investing LLC now owns 2,185 shares of the company’s stock worth $38,000 after purchasing an additional 882 shares during the period. 99.00% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on QDEL. UBS Group reissued a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. JPMorgan Chase & Co. increased their target price on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a report on Wednesday, July 1st. Citigroup raised their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Finally, Jefferies Financial Group restated a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Three equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $13.62.

QuidelOrtho Price Performance

Shares of QuidelOrtho stock opened at $14.30 on Monday. The stock has a market cap of $980.55 million, a P/E ratio of -0.93 and a beta of 0.68. The company has a debt-to-equity ratio of 1.43, a quick ratio of 0.76 and a current ratio of 1.39. The stock’s fifty day moving average is $15.80 and its 200 day moving average is $16.89. QuidelOrtho Corporation has a one year low of $9.92 and a one year high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.18. The business had revenue of $630.90 million during the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%.QuidelOrtho’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.12 earnings per share. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Sell-side analysts anticipate that QuidelOrtho Corporation will post 0.75 earnings per share for the current year.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.